Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Anti-Virulence Therapy"

Infex Therapeutics Reports Positive Phase 2a Results for RESP-X in Chronic Respiratory Infection Treatment

Phase 2a study findings show RESP-X demonstrated safety, favourable dosing potential and encouraging efficacy signals, supporting further clinical development for respiratory patients colonised with Pseudomonas aeruginosa.

Anti-Virulence Therapy | 25/05/2026 | By News Bureau

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members